BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Strong Buy" and an average price target of $105.26. The average 1-year stock price forecast is 28.38% higher than the current stock price, while the lowest is $80 (-2.43%) and the highest is $157 (+91.49%).

Price Target: $105.26 (+28.38%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$80	$105.26	$101	$157
Change	-2.43%	+28.38%	+23.19%	+91.49%

Analyst Ratings

The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	16	16	15	16	14	14
Buy	5	6	6	6	6	6
Hold	1	1	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	22	23	23	24	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $111	Buy	Maintains	$111	+35.38%	Aug 3, 2026
Myles Minter William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Aug 3, 2026
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $120	Buy	Reiterates	$120	+46.36%	Jul 24, 2026
Jason Zemansky Bank of America Securities	Bank of America Securities	Buy Maintains $101	Buy	Maintains	$101	+23.19%	Jul 22, 2026
Eric Joseph Citi	Citi	Hold Reiterates $82 → $93	Hold	Reiterates	$82 → $93	+13.43%	Jul 16, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

961.16M

Increased by 91.44%

from 502.08M

Revenue Next Year

1.61B

Increased by 67.43%

from 961.16M

EPS This Year

-2.14

from -3.78

EPS Next Year

0.57

from -2.14

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	69.72M	77.65M	9.30M	221.90M	502.08M	961.16M
Revenue Growth	745.15%	11.38%	-88.02%	2,285.27%	126.26%	91.44%
Gross Profit	66.60M	74.21M	6.86M	218.02M	481.11M	890.42M
Gross Margin	95.53%	95.58%	73.71%	98.25%	95.82%	92.64%
Operating Income	-573.33M	-468.44M	-599.44M	-577.37M	-502.06M	-303.77M
Net Income	-562.54M	-481.18M	-643.20M	-535.76M	-724.93M	-452.72M
EPS	-	-	-	-	-3.78	-2.14
Free Cash Flow	-301.13M	-285.88M	-240.16M	-291.12M	-325.29M	-266.36M
No. Analysts	-	-	-	-	-	20

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	1.0B
Avg	961.2M
Low	844.4M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	106.0%
Avg	91.4%
Low	68.2%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.50
Avg	-2.14
Low	-2.58

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-

Data Sources: S&P Global Market Intelligence and TipRanks Last updated: Aug 3, 2026

Price targets, consensus ratings and financial forecasts are provided by S&P Global Market Intelligence. Individual analyst data is provided by TipRanks. Price targets and consensus ratings update every hour to every three days, while individual analyst data updates in near real-time.

Last checked:

Aug 3, 2026

Data Sources Report a data error